ClinicalTrials.gg
RecruitingNCT07885696Updated Oct 21, 2026

Acupressure as Complementary Analgesia in Shock Wave Lithotripsy

An interventional study of Acupressure and Sham Acupressure in Acupressure, Urinary Calculi and Urolithiasis, sponsored by Medipol University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Medipol University · Not applicable, Interventional, and Supportive care

Updated Oct 21, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aims to evaluate the efficacy of acupressure applied to the LI4 (Hegu) and Qiu points before Extracorporeal Shock Wave Lithotripsy (ESWL) in patients with kidney or proximal ureteral stones. The study compares intraprocedural pain scores and procedural tolerance between an acupressure group, a sham acupressure group, and a standard care control group.

Read the detailed description

Extracorporeal shock wave lithotripsy (ESWL) is a widely used non-invasive treatment for urinary tract stones; however, procedure-related pain can lead to patient movement and irregular breathing, which may reduce treatment efficacy and cause premature termination of the session. To manage this pain without the adverse effects associated with pharmacological agents, this prospective, randomized, sham-controlled, three-arm clinical trial evaluates the analgesic efficacy of acupressure during ESWL. A total of 105 eligible adult patients scheduled for their first ESWL session will be randomly assigned in a 1:1:1 ratio to an acupressure group, a sham group, or a standard care control group. Immediately prior to the procedure, the acupressure group will receive rhythmic thumb pressure on the bilateral LI4 (Hegu) and stone-side Qiu points for a total of 9 minutes (3 minutes per point). The sham comparator group will receive superficial touch on the exact same points for the same duration without therapeutic pressure, effectively blinding the patients to the intervention. The control group will receive standard care with no additional pre-procedural physical intervention. Throughout the ESWL procedure, pain severity will be systematically monitored using a 10-cm Visual Analogue Scale (VAS) at baseline, 10, 20, 30, and 40 minutes, and at the end of the procedure. Additionally, secondary outcomes including procedural intolerance, the need for rescue analgesia, changes in hemodynamic parameters (heart rate and blood pressure), overall patient satisfaction, and stone-free rates at three weeks post-procedure will be recorded to determine if acupressure serves as a safe and effective complementary analgesic method.

02

Conditions studied

  • Acupressure
  • Urinary Calculi
  • Urolithiasis
  • ESWL
  • Pain Score (VAS)

Keywords

  • acupressure
  • eswl
  • pain score
03

In context

Urinary Calculi

160 studies on the registry are indexed under Urinary Calculi; 29 are open to participants now.

This study's planned enrollment of 105 is close to the median of 110 across 111 interventional studies indexed under Urinary Calculi.

Browse Urinary Calculi studies →

Lead sponsor

Medipol University is the lead sponsor of 320 studies on the registry; 87 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for ESWL due to kidney or proximal ureteral stones.
  • First-time ESWL patients.
  • Age ≥ 18 years.

Exclusion criteria

Exclusion Criteria:

  • Kidney anomaly (e.g., horseshoe kidney) or severe hydronephrosis.
  • Morbid obesity.
  • Chronic neuropathic disease that may affect pain perception or neural response to acupressure.
  • Use of any analgesics within [12/24] hours prior to the procedure.
  • Use of anticoagulants.
  • Impaired skin integrity (wound, infection, tenderness) at the acupressure application sites (LI4 or Qiu).
  • Amputation of the relevant extremity.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Acupressure Group

    Patients receive superficial touch without pressure on the identical points (bilateral LI4 and stone-side Qiu) for the same duration (9 minutes) immediately before ESWL.

    Behavioral: Acupressure

  • Sham comparator
    Sham Group

    Patients receive superficial touch without pressure on the identical points (bilateral LI4 and stone-side Qiu) for the same duration (9 minutes) immediately before ESWL.

    Behavioral: Sham Acupressure

  • No intervention
    Control Group

    Patients receive standard ESWL protocol without any additional intervention or touching before the procedure.

Interventions

  • BehavioralAcupressure

    Rhythmic thumb pressure applied to LI4 (Hegu) and Qiu points at a subjective intensity of warmth/heaviness without causing pain.

  • BehavioralSham Acupressure

    Superficial touch mimicking the duration and location of acupressure without applying therapeutic pressure.

06

What researchers measure

Primary outcomes

  1. Pain Severity Assessed by Visual Analogue Scale (VAS)

    Patients self-reported pain intensity on a 10-cm horizontal line (0 = no pain, 10 = worst possible pain).

    Time frame: Baseline, 10, 20, 30, and 40 minutes during ESWL, and at the end of the procedure.

Secondary outcomes

  1. Procedural Intolerance

    Premature termination of the ESWL procedure before reaching the planned shock number due to severe pain.

    Time frame: Up to the end of the procedure (approximately 45 minutes).

  2. Need for Rescue Analgesia

    Number of patients requiring additional analgesia (e.g., paracetamol/NSAID) during the procedure.

    Time frame: During the ESWL procedure.

  3. Patient Satisfaction

    Evaluated via a 5-point Likert scale (1: very dissatisfied, 5: very satisfied).

    Time frame: At the end of the procedure.

07

Study locations

1 of 1 sites recruiting
  • istanbul başakşehir Çam Sakura city hospital
    Istanbul, Turkey (Türkiye)
    Recruiting
08

References and documents

Publications

  • Ziaei Azarkhavarani F, Rejeh N, Valiani M, Kazemi R. Effect of acupressure on pain among older female patients undergoing extracorporeal shock wave lithotripsy: A randomized controlled clinical trial. Explore (NY). 2024 Mar-Apr;20(2):233-238. doi: 10.1016/j.explore.2023.07.010. Epub 2023 Aug 2. PubMed 37573221 ↗
  • Safdari A, Khazaei S, Biglarkhani M, Mousavibahar SH, Borzou SR. Effect of acupressure on pain intensity and physiological indices in patients undergoing extracorporeal shock wave lithotripsy: a randomized double-blind sham-controlled clinical trial. BMC Complement Med Ther. 2024 Jan 25;24(1):55. doi: 10.1186/s12906-024-04360-1. PubMed 38273233 ↗

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07885696
Lead sponsor
Medipol University
Responsible party
Ali Ihsan Memmi (medical doctor, Medipol University) — Principal investigator
First posted
Oct 21, 2026
Start date
Oct 10, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 21, 2026

Study contacts

ALi İhsan memmi, medical doctor
Contact
alimemmi@gmail.com
+90 5379220977

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion